Cortexyme, Inc. (NASDAQ:CRTX) crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $34.10 and traded as high as $41.90. Cortexyme shares last traded at $39.30, with a volume of 1,545 shares.
Several analysts recently issued reports on CRTX shares. JMP Securities started coverage on shares of Cortexyme in a report on Monday, June 3rd. They set a “mkt outperform” rating and a $53.00 price objective for the company. Bank of America reissued a “buy” rating and issued a $25.00 price target on shares of Infineon Technologies in a report on Monday, June 3rd. Canaccord Genuity increased their price target on shares of B2Gold from C$5.25 to C$5.75 in a report on Monday, June 3rd. Finally, Credit Suisse Group reduced their price target on shares of FOX from $51.00 to $45.00 and set an “outperform” rating for the company in a report on Monday, June 3rd.
The stock’s fifty day simple moving average is $34.10.
In related news, major shareholder Pfizer Inc purchased 50,000 shares of Cortexyme stock in a transaction on Monday, May 13th. The stock was purchased at an average cost of $17.00 per share, with a total value of $850,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Cortexyme Company Profile (NASDAQ:CRTX)
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease.
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.